Daniel J. O'Connor insider trades: Ambrx Biopharma (AMAM) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Daniel reports to the SEC
and 2 more companies
Open-market buys and sales
18 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 27, 2023 | AMAM | ↓ Sell | 50,012 | $9.82 | $491K | Direct | Oct 31, 2023 (4d) |
| Jun 1, 2022 | SEEL | ↑ Buy | 16,000 | $0.61 | $10K | Direct | Jun 2, 2022 (1d) |
| Apr 30, 2021 | ONCS | ↓ Sell | 3,172 | $4.86 | $15K | Direct | May 4, 2021 (4d) |
| Feb 1, 2021 | ONCS | ↓ Sell | 3,413 | $7.71 | $26K | Direct | Feb 2, 2021 (1d) |
| Nov 2, 2020 | ONCS | ↓ Sell | 3,280 | $3.79 | $12K | Direct | Nov 3, 2020 (1d) |
| Jul 31, 2020 | ONCS | ↓ Sell | 3,133 | $4.20 | $13K | Direct | Aug 4, 2020 (4d) |
| Apr 30, 2020 | ONCS | ↓ Sell | 3,075 | $1.79 | $6K | Direct | May 4, 2020 (4d) |
| Jan 31, 2020 | ONCS | ↓ Sell | 2,654 | $1.96 | $5K | Direct | Feb 3, 2020 (3d) |
| Oct 31, 2019 | ONCS | ↓ Sell | 2,128 | $2.16 | $5K | Direct | Nov 1, 2019 (1d) |
| Nov 7, 2018 | ONCS | ↑ Buy | 10,000 | $0.91 | $9K | Direct | Nov 7, 2018 (0d) |
| Feb 5, 2018 | ONCS | ↑ Buy | 16,667 | $1.50 | $25K | Direct | Feb 6, 2018 (1d) |
| Nov 2, 2016 | ADXS | ↓ Sell | 8,240 | $8.32 | $69K | Direct | Nov 2, 2016 (0d) |
| May 2, 2016 | ADXS | ↓ Sell | 8,237 | $7.51 | $62K | Direct | May 2, 2016 (0d) |
| Jan 29, 2016 | ADXS | ↓ Sell | 8,818 | $6.88 | $61K | Direct | Feb 1, 2016 (3d) |
| Oct 30, 2015 | ADXS | ↓ Sell | 8,350 | $12.26 | $102K | Direct | Nov 3, 2015 (4d) |
| Jul 31, 2015 | ADXS | ↓ Sell | 8,449 | $15.44 | $130K | Direct | Aug 4, 2015 (4d) |
| Mar 31, 2014 | ADXS | ↑ Buy | 3,333 | $3.00 | $10K | Direct | Apr 2, 2014 (2d) |
| Oct 24, 2013 | ADXS | ↑ Buy | 13,500 | $4.00 | $54K | Direct | Oct 28, 2013 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Daniel J. O'Connor's insider trades
Daniel J. O'Connor is President and CEO at Ambrx Biopharma (AMAM). Since Oct 24, 2013, Daniel has reported 5 open-market purchases worth $108K and 13 sales worth $998K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (66 filings), shares withheld for taxes (34 filings), other transactions (3 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AMAM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.